Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25328626 | 0.68 | KMT2A (0.37) | ALDH1A1 | |
| SCHEMBL30928807 | 0.68 | CYP11B2 (0.33) | CYP11B2 | |
| SCHEMBL28083642 | 0.67 | IDO1 (0.45) | ALDH1A1 | |
| SCHEMBL154217 | 0.66 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL2650519 | 0.66 | TSHR (0.42) | ALDH1A1 | |
| SCHEMBL992858 | 0.66 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4921753 | 0.64 | HPGDS (0.39) | ALDH1A1 | |
| SCHEMBL2656822 | 0.64 | AR (0.40) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL29434547 | 0.62 | KDM4E (0.46) | ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL2429966 | 0.62 | KDM4E (0.46) | ALDH1A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3800186-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| EP-3322702-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2019-11-20 | — | — | EP | disclosed |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | ALDH1A1 875/4885MAPK1 1722/4885CYP11B1 1015/4885 |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | ALDH1A1 875/4885MAPK1 1722/4885CYP11B1 1015/4885 |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | ALDH1A1 875/4885MAPK1 1722/4885CYP11B1 1015/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | ALDH1A1 875/4885MAPK1 1722/4885CYP11B1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.